Steven R. Gerbsman, Principal of Gerbsman Partners and Robert Tillman, a member of the Gerbsman Partners Board of Intellectual Capital, announced today their success in maximizing stakeholder value for a venture backed life science company that was a pioneer in endovascular therapeutic cooling.
Gerbsman Partners provided leadership to the company and its senior lender with:
- Crisis Management experience in developing the strategic action plans for maximizing the value of the business, its Intellectual Property and assets;
- Proven domain technology expertise in maximizing the value of the business and Intellectual Property through a targeted M&A plan;
- The ability to "Manage the Process" among potential Acquirers, Lawyers, Creditors, Management and Advisors;
- The proven ability to "Drive" toward successful closure for all parties at interest.
Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property. In the past 60 months, Gerbsman Partners has been involved in maximizing value for 35 Technology and Life Science companies and their Intellectual Property and has restructured/terminated over $725 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception, Gerbsman Partners has been involved in over $2.1 billion of financings, restructurings and M&A transactions.
Gerbsman Partners has offices and strategic alliances in North America, Europe and Israel.